RxDoctor Payments Data

Mohammad Alkotob, MD

Cardiovascular Disease · Flushing, MINPI 1598792830

Payments from drug & device makers

$10,178in general payments, 2019–2025

Across 339 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biotronik Inc.$2K
  • Novartis$1K
  • Cardiovascular Systems Inc.$886
  • Amgen$627
  • Merck$428
  • plus $3K from 40 others

What the payments were for

  • Consulting fees$220%
  • Travel & lodging$3,62536%
  • Food & beverage$6,38763%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,178 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$269,259
Medicare patients
376
Services billed
1,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$137,526
Repatha SureclickEvolocumab65$49,787
EntrestoSacubitril/Valsartan37$44,277
BrilintaTicagrelor48$27,368
MultaqDronedarone Hcl13$20,762
XareltoRivaroxaban20$20,290
JardianceEmpagliflozin14$8,409
Rosuvastatin Calcium129$2,014
Atorvastatin Calcium126$1,673
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$1,359
Metoprolol Succinate80$1,318
Metoprolol Tartrate167$1,289
Losartan Potassium109$1,084
Amlodipine Besylate116$980
Flecainide Acetate12$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$381$137,526113 claims
NovartisEntresto$1,110$44,27737 claims
AstraZenecaBrilinta$306$27,36848 claims
Sanofi-aventis U.S. LLCMultaq$69$20,76213 claims
Johnson & JohnsonXarelto$336$20,29020 claims
Boehringer IngelheimJardiance$146$8,40914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Flushing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →